{"prompt": "['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 58 of 92', 'CR845-CLIN3103', 'Inflammatory biomarkers', 'Missed dialysis visits', '6.5.5.1', 'Inflammatory Biomarkers', 'Inflammatory biomarkers, such as interleukin (IL)-6, IL-8, and granulocyte', 'macrophage-colony stimulating factor will be measured, as defined in the statistical', 'analysis plan (SAP). A blood sample of sufficient volume to provide for replicate assays', 'of each biomarker will be collected prior to dialysis per the schedules of events.', 'Detailed instructions for biomarker sample collection and processing will be provided in', 'the laboratory manual.', '6.5.5.2', 'Missed Dialysis Visits', 'The number and reason(s) for missed dialysis will be recorded.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 59 of 92', 'CR845-CLIN3103', '7.0', 'Discussion and Justification of Study Design', '7.1', 'Discussion of Study Design and Choice of Control Groups', 'The double-blind part of the study was designed to evaluate the efficacy and safety of', 'IV CR845 in hemodialysis patients with moderate-to-severe pruritus. A randomized,', 'double-blind design was chosen to minimize bias. A 12-week duration of treatment was', 'selected to demonstrate durability of the efficacy observed in a prior 8-week treatment', 'study (ie, Study CR845-CLIN2101) and to further evaluate safety during a longer', 'exposure. The primary efficacy endpoint was determined using the Worst Itching', 'Intensity NRS scale, which measures itching intensity over 24 hours. This scale has been', 'validated for this patient population and is identical to the primary efficacy endpoint used', 'in the dose-ranging, Phase 2 study, CR845-CLIN2101.', 'The open-label part of the study was designed to evaluate the long-term safety of CR845', '0.5 mcg/kg IV administered after each dialysis session (generally 3 times per week for up', 'to 52 weeks) in patients who completed the 12-week Double-blind Treatment Period of', 'this study. This design is commonly used in clinical development to obtain long-term', 'safety information. The duration of the study is in accordance with International Council', 'for Harmonisation (ICH) and FDA guidance [Guidance for Industry February 2016].', '7.2', 'Selection of Doses in the Study', 'The combined safety, pharmacokinetic, and efficacy data from CR845-CLIN2101', 'provided the basis for the selection of the dose and dose regimen of CR845 to be used in', 'this study. The lowest dose tested (0.5 mcg/kg IV) appeared to be well tolerated and', 'effective at reducing itch intensity over a period of 8 weeks.', '7.3', 'Appropriateness of Measurements', 'Standard clinical, laboratory, and statistical procedures and methodology will be utilized', 'in this study. The PRO assessments to be used in this study are appropriate.', '10 September 2019', 'Version 2.2']['Cara Therapeutics, Inc., CR845', 'IND 123140, SN 0072', 'Cara Therapeutics Inc.', 'Confidential', 'Page 60 of 92', 'CR845-CLIN3103', '8.0', 'Statistical Methods', '8.1', 'General Considerations', 'This section describes the statistical analysis of efficacy and safety data collected during', 'the Double-blind Phase only. The analysis of safety and efficacy data collected during', 'the Open-label Extension Phase will be included in the SAP.', 'The SAP will provide a detailed description for the handling of missing data, patient', 'eligibility criteria for the analysis, and statistical methodology. If differences occur', 'between analyses of double-blind data described in the SAP and the current protocol,', 'those found in the SAP will assume primacy. In addition, the SAP will provide details', 'for the analysis of data collected during the Open-label Extension Phase, including the', 'analysis of safety data during exposure to CR845 across both the Double-blind and the', 'Open-label Extension Phases.', 'Unless otherwise noted, continuous variables will be summarized using number of', 'non-missing observations, mean, standard deviation, median, minimum, and maximum;', 'categorical variables will be summarized using the frequency count and the percentage of', 'patients in each category. In addition to the descriptive summaries, pertinent data listings', 'will be provided.', 'All analyses will be performed using SAS version 9.2 or higher, unless otherwise', 'specified.', '8.2', 'Determination of Sample Size', 'The planned sample size for this study is 350 (175 per treatment group) male and female', 'hemodialysis patients with chronic moderate-to-severe pruritus (mean baseline 24-hour', 'Worst Itching Intensity NRS score 5), randomized at approximately 95 clinical sites.', 'The sample size may be increased to 500 patients (250 per treatment group) based on the', 'results of a planned unblinded interim assessment conducted when approximately 50% of', 'the planned 350 first patients have been randomized and have either completed the', '12-week Double-blind Treatment Period or have discontinued from double-blind', 'treatment early. The planned interim assessment will be conducted by an Independent', 'Data Monitoring Committee (IDMC). Details related to the sample size re-estimation are', 'included in Section 8.4.1.', 'The sample size calculation is based on results of a completed Phase 2 double-blind,', 'placebo-controlled study (CR845-CLIN2101) of CR845 in hemodialysis patients who', 'had moderate-to-severe pruritus. In this study, approximately 30% of patients', 'randomized to the placebo group reported 3-point improvement from baseline with', 'respect to the 24-hour Worst Itching Intensity NRS at the end of treatment (Week 8).', 'The proportion of patients who received CR845 and reported a similar improvement in', 'itch scores ranged from approximately 60% to 45% (ie, 30% to 15% difference from', '10 September 2019', 'Version 2.2']\n\n###\n\n", "completion": "END"}